BioPharma Resources

Drug Trial Radar · NCT06340568

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Jun 10, 2025

Primary completion

Mar 2028

Study completion Nov 2029

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
DualityBio Inc.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
First posted
Apr 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \[or docetaxel, if participants cannot take paclitaxel\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs). In Cohort 2, the main goal is to assess how well BNT323 works by determining the objective response rate (ORR), that is, the percentage of participants whose tumor shrinks (partial response) or disappears (complete response) after treatment. The safety of BNT323 will also be assessed by following the occurrence of unfavorable/adverse effects that are seen after treatment. Other measures include the pharmacokinetics of BNT323 (or how BNT323 moves through and out of the body), the body's immune response, and the impact on quality of life.

Conditions

  • Endometrial Cancer

Interventions

  • BNT323/DB-1303Drug

    intravenous (IV) infusion

  • DoxorubicinDrug

    IV bolus or infusion

  • PaclitaxelDrug

    IV infusion

  • DocetaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: PFS assessed by blinded independent central review (BICR) in participants with HER2 IHC 1+/2+ recurrent endometrial cancerTime frame: Up to approximately 53 months
  2. Cohort 2: ORR assessed by BICR in participants with HER2 IHC 3+ recurrent endometrial cancerTime frame: Up to approximately 53 months

Locations

214 sites in 27 countries. Site status is shown where the registry gives one.

  • USC/Norris Cancer Center

    Los Angeles, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Broward Health Medical Center

    Fort Lauderdale, Florida · Recruiting

  • OSF Saint Francis Medical Center

    Peoria, Illinois · Recruiting

  • Carle Cancer Institute

    Urbana, Illinois · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • WK Cancer Center

    Shreveport, Louisiana · Recruiting

  • Minnesota Oncology

    Minneapolis, Minnesota · Recruiting

  • The Center of Hope Reno

    Reno, Nevada · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • SUNY Upstate Medical University

    Syracuse, New York · Recruiting

  • Miami Valley Hospital South

    Centerville, Ohio · Recruiting

  • Ohio State University

    Hilliard, Ohio · Recruiting

  • Peggy & Charles Stephenson Oklahoma Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Asplundh Cancer Pavilion

    Willow Grove, Pennsylvania · Recruiting

  • Sanford Cancer Center

    Sioux Falls, South Dakota · Recruiting

  • Texas Oncology, P.A.

    Tyler, Texas · Recruiting

  • Intermountain Healthcare

    Murray, Utah · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Centro de Oncologia Dr. Doreski - Fundación Respirar

    Buenos Aires, Argentina · Recruiting

  • Centro de Investigaciones Medicas Mar del Plata

    Buenos Aires, Argentina · Recruiting

  • Hospital Británico de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • CEMAIC - Centro Medico Privado

    Córdoba, Argentina · Recruiting

  • Investigaciones CORI S.R.L.

    La Rioja, Argentina · Recruiting

  • COIR Fundacion Centro Oncologi, de Integracion Regional

    Mendoza, Argentina · Recruiting

  • Fundación Oncológica Mendoza

    Mendoza, Argentina · Recruiting

  • Hospital Provincial del Centenario

    Rosario, Argentina · Recruiting

  • Centro Oncológico de Excelencia

    San Juan, Argentina · Recruiting

  • Clinica Mayo de Urgencias

    San Miguel de Tucumán, Argentina · Recruiting

  • Adelaide Oncology & Haematology

    Adelaide, Australia · Recruiting

  • Cancer Research SA

    Adelaide, Australia · Recruiting

  • Monash Health Clinical Trial Center

    Clayton, Australia · Recruiting

  • Gosford Hospital

    Gosford, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • Frankston Hospital

    Melbourne, Australia · Recruiting

  • Shoalhaven Cancer Care Centre

    Nowra, Australia · Recruiting

  • Sunshine Hospital

    Saint Albans, Australia · Recruiting

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.